Volume : 08, Issue : 01, January – 2021
24. IMPORTANCE AND EFFICACY OF LONG ACTING Β2 AGONIST SALMETEROL, IN THE TREATMENT OF MILD TO MODERATE ASTHMA
Dr Rohina Masood, Dr Khudeja Abid, Dr Aliza Nasir
Aim: To evaluate the role of salmeterol in adjuvant therapy with inhaled corticosteroids in patients with mild to moderate asthma.
Study design: A Randomized clinical trial
Place and duration of studies: The study was conducted at the Medicine Unit-II of Sir Gang ram Hospital Lahore for one-year duration from August 2019 to August 2020.
Methodology: Fifty patients with mild to moderate asthma aged 15-65 years were divided into two groups. Patients in the study group received a combination of salmeterol 50 µg and fluticasone propionate 250 µg twice daily, patients in the control group received beclomethasone dipropionate 500 µg twice daily. The endpoints were reduction in Symptom Score and improvement in maximum expiratory flow (PEFR) checked every two weeks. The paired student test was used to analyze the data.
Results: In patients in the study group, the mean total symptom score decreased significantly from 11.16 from baseline to 0.41 (p <0.001) at the end of the study, and the mean PEFR increased significantly from 189.4 L / min ± 0. 34 to 354.58 l / min, 0.15; P-value <0.001. While in the control group, the reduction in the mean total symptom score and the increase in mean PEFR was negligible, i.e. Total symptom score 11.04 from baseline to 5.29 and mean PEFR reduced from 182.60 L / min ± 17, 05 to 231.73L / min ± 13.84.
Conclusion: Salmeterol plays a significant role in the treatment of mild to moderate patients with asthma.
Keywords :beclomethasone dipropionate, fluticasone, inhaled corticosteroids, peak expiratory flow, salmeterol, symptom score.
Cite This Article:
Please cite this article in press Rohina Masood et al, Importance And Efficacy Of Long Acting Β2 Agonist Salmeterol, In The Treatment Of Mild To Moderate Asthma., Indo Am. J. P. Sci, 2021; 08(01).
Number of Downloads : 10